Medication Questions Deserve Data, Not Shame in Either Direction

Key takeaways

• Choose two goals you can see and count before any medication decision.
• Match treatment to the child’s age, impairment, health, and preferences.
• Track benefit, side effects, and daily function with a planned review date.
• Medication and behavior support can work together, without shame in either direction.

A made-up scene.

Your child’s teacher has sent three worried notes. Homework now ends in tears. A relative says medication will change your child. A church friend says refusing it shows more faith. You leave both talks feeling judged. The real question is simpler than either speech: what would help this child function and feel well, and how would you know.

Start with a decision you can test

Start an ADHD treatment choice with a careful review. ADHD is short for attention-deficit/hyperactivity disorder. It is a health condition. It can affect attention, impulse control, activity, or some mix of these. Symptoms must cause harm in more than one setting. Other causes and health needs also need a close look.

Then name two goals in plain language. “Do better” is hard to measure. “Finish the morning routine with one reminder on four school days” is clearer. So is “turn in at least four of five weekly assignments.” The American Academy of Pediatrics, or AAP, recommends clear target outcomes. Reports should come from parents, teachers, and the child. [1-3]

Set a review date before the plan begins. Use the same short rating scale, school data, or behavior count at each check. A Vanderbilt follow-up form can track core symptoms and daily work. It can also track common side effects. It supports a care visit. It does not make the diagnosis by itself.

This is like choosing eyeglasses after an eye exam. A neighbor may love one prescription. Another may hate it. Their story cannot reveal what your child’s eyes need. Good care measures the problem. It tries a suitable option. Then it checks whether daily life becomes clearer.

Zoom

Age changes the first step

For children ages four through five, the AAP recommends parent training and/or classroom behavior care first, when available. Methylphenidate may be considered when those supports have run for several months without enough benefit and moderate to severe difficulty continues. Methylphenidate is not FDA-approved below age six, so this is off-label use that a prescriber must weigh openly with the family. [1] In June 2025 the FDA also required expanded labeling about weight loss in children younger than six taking extended-release stimulants, and noted that these children reach higher drug levels and more side effects than older children. Ask the prescriber which formulation is proposed and how growth will be watched. [4]

For ages six through eleven, the guideline recommends an approved ADHD medicine. Parent training and/or classroom behavior care should join it. Medicine with both forms of support is preferred when possible. School services may include an Individualized Education Program. They may also include a Section 504 plan. For ages twelve through seventeen, medication can be offered with the teen’s assent. Evidence-based behavior and school supports are still encouraged. [1]

These age bands guide care. They do not replace a case-by-case choice. A clinician should also review sleep, anxiety, depression, trauma, learning problems, substance use, tics, and family heart history. Some of these can look like ADHD. Others can occur beside it.

What medication evidence can answer

Short trials show that several ADHD medicines reduce core symptoms better than placebo. A large network meta-analysis compared 133 randomized trials. In children and teens, its short-term findings favored methylphenidate as a first choice. This applied when medicine was indicated. Most trials lasted about twelve weeks. The study could not settle long-term benefit or harm. [5]

The Multimodal Treatment Study of ADHD, called the MTA, enrolled 579 children aged seven to ten, all with the combined presentation of ADHD. After fourteen months, carefully managed medication improved core symptoms. It did better than intensive behavior treatment alone or usual community care. Combined care offered modest gains for some noncore and functional outcomes. It was not clearly better than medication management for every core symptom. [6,7]

Those results do not prove that every child should take medicine. They also do not prove a lasting effect from years of treatment. After the trial phase, families chose their own care. Later MTA follow-up was observational. Group differences cannot show what medication caused over time. [8]

Medication response varies. A useful trial asks two questions. Did the target function improve? Was the burden acceptable? The AAP advises titration. This means a prescriber adjusts treatment to seek benefit with tolerable side effects. [1]

Monitor benefit and burden together

Stimulants commonly cause lower appetite, stomach pain, headache, or sleep trouble. Average blood pressure and heart rate changes are small. Some children have larger changes. Clinicians monitor growth, pulse, and blood pressure. They also track sleep, mood, and appetite. The AAP guideline describes a one-to-two-centimeter drop in predicted adult height. That group estimate cannot predict one child’s outcome. [1,9,10]

Nonstimulants have different patterns. Atomoxetine may cause sleepiness, stomach symptoms, or reduced appetite. It carries an FDA boxed warning, the agency’s strongest warning, for increased suicidal thinking in children and teens. The label asks families to watch closely and to report any sudden change in mood, behavior, thinking, or feelings, especially during the first few months and after any dose change. The label also names two problems that need urgent contact: yellowing skin or eyes, dark urine, right upper stomach pain, or unexplained flu-like symptoms, which can signal liver injury; and a prolonged or painful erection in a boy, which needs immediate medical care. Alpha-2 agonists may cause sleepiness, dizziness, dry mouth, or lower pulse and blood pressure. They should not be stopped suddenly without prescriber guidance. [1,11]

At the first visit, ask whom to call after hours and which symptoms mean emergency care. Do not start, stop, share, or change a child’s medication from an article. Do not copy another family’s plan.

Prescription stimulants also carry an FDA boxed warning about misuse, abuse, addiction, and overdose. FDA tells families to store the medicine securely, out of sight and reach of children and where others including visitors cannot reach it, never to let a child share it with anyone, and to dispose of unused or expired medicine promptly or at a drug take-back site. As a child moves into the teen years, ask the prescriber how the plan will check for misuse or diversion. [9,10,12]

Tracking should include more than quiet behavior. Ask whether your child learns and joins family life. Ask about friends, sleep, food, and sense of self. A child who sits still but feels bad has not reached the goal. A lower score with no gain in daily life may call for a new plan.

Behavior support is active treatment

Parent training teaches adults to notice triggers and give clear directions. It also teaches rewards and calmer responses. It is not a verdict on parenting. Meta-analytic evidence supports small to moderate gains in disruptive behavior and parenting outcomes. Follow-up benefits can persist for several months, with a mean follow-up of about five months. Studies differ, and the analyses of which techniques matter most are exploratory rather than settled. [13,14]

One 2024 randomized trial in Brazil found that parent training, delivered online or face to face, reduced ADHD and oppositional symptoms compared with a waiting list. It is a single trial, not pooled evidence. [15]

Behavior care and medication answer different parts of family life. Medicine may lower the symptom load during its active hours. Skills and systems can shape routines, praise, school communication, and conflict. Neither option proves virtue. Neither option proves failure.

Shame is poor clinical data

Parents often balance benefit against side effects, identity concerns, and social judgment. A research review found that stigma and others’ disapproval can shape treatment choices and adherence. It also found that care works best when clinicians invite family concerns instead of dismissing them. [16]

Religion can shape these conversations, but no church member speaks for every Christian. One older United States survey found that evangelical respondents were less likely than some peers to call ADHD a disease or favor medication. Church attendance itself was not linked to medication beliefs. It was linked with being more likely to see ADHD as a real condition. The survey measured attitudes in 2002, so it cannot define a present family or congregation. [17]

Ask advisers for evidence, not moral labels. “What change should we expect?” is useful. So are “How soon will we review it?” and “What would make us change course?” A warm opinion can still be wrong. A cold clinical visit can also miss what matters to the family.

Where science meets the soul

In Matthew 9, Jesus eats with people whom religious leaders kept at a distance. When challenged, he says, “Those who are well have no need of a physician, but those who are sick” (Matthew 9:12, ESV). The next verse joins that image to mercy and Jesus’ mission toward sinners. The passage is about his company and mission, not a rule about psychiatric medication. In the saying, “the sick” stands for the people the religious leaders had labeled sinners. It does not mean that a child who needs treatment is morally sick.

Willoughby Allen reads Matthew’s Hosea quotation as a contrast between mercy and ritual emphasis within Jesus’ divine mission. A. B. Bruce says a physician goes where need is and reads Jesus’ table fellowship as a mission of mercy toward people the Pharisees called sinners. [18,19]

The bridge is limited but useful. Clinical care and this passage both turn attention toward need rather than social rank. The analogy stops there. Matthew did not predict ADHD science, and medicine does not carry the gospel’s saving meaning.

This text should never be used to shame parents who choose medication. It should not shame those who defer it after a sound evaluation. Mercy makes room for facts, questions, and revision. Biblical wisdom can guide motives and care, but it complements rather than replaces professional evaluation and treatment.

Build a two-goal review plan

Start with one page. Write the diagnosis being considered or treated. Add two observable goals, one measure, and a review date. Then record the supports already in place.

Use this sequence:

1. Ask the clinician what evidence supports the proposed option for this age and symptom pattern.
2. Define two goals across daily life, such as school completion and fewer unsafe impulsive acts.
3. Choose one weekly measure from home and one from school when possible.
4. Record sleep, appetite, mood, pulse, blood pressure, and growth as the clinician directs.
5. Keep behavior support and school accommodations active while results are reviewed.
6. At the planned visit, decide whether to continue, adjust, switch, pause, or gather more data with the prescriber.

Invite the child into language that fits their age. Ask what feels easier, harder, or different. Teens should have real voice in the decision. If family members disagree, return to the goals and observations.

What is known and what is not

ADHD medication can reduce core symptoms for many children during short controlled trials. Parent training can improve disruptive behavior and family practices. Guidelines support combining medication, behavior care, and school support for many school-age children. [1,5,13-15]

Research cannot identify the perfect plan from a diagnosis alone. Long-term comparative evidence is thinner than short-term evidence. Ratings can be influenced by expectations. Access to trained clinicians, parent programs, and school services also varies.

No study can settle a family’s moral worth. Faith communities can offer meals, rides, patience, and freedom from blame. They should not prescribe or forbid treatment from the sidelines. The safe question is whether the plan helps daily life at a cost the child can bear.

When to seek urgent help

Chest pain, shortness of breath, or fainting during stimulant treatment is an emergency. Do not wait at home for a return call while symptoms continue. The FDA Medication Guide tells families to call the prescriber or go to the nearest hospital emergency room right away. Hearing voices, seeing or believing things that are not real, or new manic symptoms need an immediate call to the prescriber, and emergency care if the child cannot stay safe. Fingers or toes that turn numb, cool, or painful, or that change color, need prompt medical review. [9,10] A prolonged or painful erection can occur with stimulants as well as with atomoxetine and needs immediate medical care. [9,11]

Any new or sudden change in mood, behavior, thinking, or feelings needs prompt same-day contact with the prescriber or a qualified mental health clinician. The current atomoxetine Medication Guide tells families to call the child’s doctor right away. [11] New suicidal thoughts need more than a message left with the office. Use the steps below the same day.

Ask your child directly and in plain words. Do not leave the child alone while risk is unclear, and do not promise secrecy. [20,21,22] Most children who report suicidal thoughts turn out to need a prompt assessment rather than emergency care, but only a trained assessment can decide that, and current AAP guidance uses a brief suicide safety assessment to make the call. [20]

Reduce access to lethal means now. During suicidal thoughts, the safest firearm is one stored away from the home, when that is safe and legal. If removal is impossible, keep it locked and unloaded, store ammunition apart, and secure keys and access codes. Lock up all medicines, including your child’s ADHD medicine, and limit the quantity on hand. Then seek real-time professional guidance now and let a trained assessment choose the setting. The child’s clinician, an urgent behavioral health service, or the national Suicide & Crisis Lifeline can help select the right level of care. [21]

Use emergency services or an emergency department if the child is currently thinking about killing themselves, has a plan with access, has made an attempt, or is in a setting that cannot be kept safe. [23]

Frequently asked questions

Does considering medication mean our faith is weak?

No. Scripture does not make accepting or declining ADHD medication a test of faith. A faithful decision can use prayer, clinical evidence, close observation, and wise counsel together.

Will stimulants change my child’s personality?

The aim is better function without flattening the child’s personality. If a child seems withdrawn, joyless, overly quiet, or unlike themselves, tell the prescriber. That response is useful data and may call for a change.

Should behavior therapy come before medicine?

Age matters. For preschool-aged children, parent training comes first. For most school-age children with significant ADHD, guidelines support medication and behavior or classroom support together. [1]

How long should a medication trial last?

There is no safe universal answer. The prescriber sets timing based on the medicine, dose process, benefit, and side effects. Agree on early follow-up and do not make changes alone.

What if parents disagree?

Write down each concern without ridicule. Then agree on two outcomes and the burden you will track. A shared visit can help a clinician explain options and uncertainty.

Are rating scales enough to diagnose ADHD?

No. Scales organize reports from home and school. Diagnosis also requires history, impairment across settings, developmental context, and a review of other causes. [1,3]

Related reading on NP FADY

• ADHD Medications Compared: Stimulants vs. Non-Stimulants for Kids and Adults
• Why ADHD Medications May Seem to Stop Working, and What Actually Helps
• IEP vs. 504 Plan: Understanding School Support Options for Students with Disabilities
• More Than Moodiness: Depression and Anxiety in Ages 9-12

References

1. Wolraich ML, Hagan JF Jr, Allan C, et al. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2019;144(4):e20192528. doi:10.1542/peds.2019-2528. PMID:31570648. https://publications.aap.org/pediatrics/article/144/4/e20192528/81590/
2. American Academy of Pediatrics. Treatment of ADHD and related disorders. HealthyChildren.org. Updated September 27, 2019. https://www.healthychildren.org/English/health-issues/conditions/adhd/Pages/Treatment-of-ADHD-and-Related-Disorders.aspx
3. National Institute for Children’s Health Quality. NICHQ Vanderbilt Assessment Scales. 2024. https://nichq.org/downloadable/nichq-vanderbilt-assessment-scales/
4. US Food and Drug Administration. FDA requires expanded labeling about weight loss risk in patients younger than 6 years taking extended-release stimulants for ADHD. Drug Safety Communication. June 30, 2025. Accessed August 27, 2026. https://www.fda.gov/drugs/drug-safety-communications/fda-requires-expanded-labeling-about-weight-loss-risk-patients-younger-6-years-taking-extended
5. Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727-738. doi:10.1016/S2215-0366(18)30269-4. PMID:30097390.
6. MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 1999;56(12):1073-1086. doi:10.1001/archpsyc.56.12.1073. PMID:10591283.
7. National Institute of Mental Health. The Multimodal Treatment of Attention Deficit Hyperactivity Disorder Study. Accessed August 27, 2026. https://www.nimh.nih.gov/funding/clinical-research/practical/mta
8. Swanson JM, Arnold LE, Molina BSG, et al. Young adult outcomes in the follow-up of the Multimodal Treatment Study of Attention-Deficit/Hyperactivity Disorder. J Child Psychol Psychiatry. 2017;58(6):663-678. doi:10.1111/jcpp.12684. PMID:28295312.
9. RITALIN (methylphenidate hydrochloride) tablets prescribing information and Medication Guide. DailyMed. Accessed August 27, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0bf0835-6a2f-4067-a158-8b86c4b0668a
10. US Food and Drug Administration. MYDAYIS (mixed salts of a single-entity amphetamine product) prescribing information and Medication Guide. Revised 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/022063s007lbl.pdf
11. STRATTERA (atomoxetine hydrochloride) capsules prescribing information and Medication Guide. DailyMed. Accessed August 27, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=309de576-c318-404a-bc15-660c2b1876fb
12. US Food and Drug Administration. FDA updating warnings to improve safe use of prescription stimulants used to treat ADHD and other conditions. Drug Safety Communication. May 11, 2023. Accessed August 27, 2026. https://www.fda.gov/drugs/drug-safety-and-availability/fda-updating-warnings-improve-safe-use-prescription-stimulants-used-treat-adhd-and-other-conditions
13. Dekkers TJ, Hornstra R, van der Oord S, et al. Meta-analysis: which components of parent training work for children with attention-deficit/hyperactivity disorder? J Am Acad Child Adolesc Psychiatry. 2022;61(4):478-494. doi:10.1016/j.jaac.2021.06.015. PMID:34224837.
14. Doffer DPA, Dekkers TJ, Hornstra R, et al. Sustained improvements by behavioural parent training for children with attention-deficit/hyperactivity disorder: a meta-analytic review of longer-term child and parental outcomes. JCPP Adv. 2023;3:e12196. doi:10.1002/jcv2.12196. PMCID:PMC10501699.
15. de Castro Paiva GC, Polanczyk GV, Miguel EC, et al. Parent training for disruptive behavior symptoms in attention deficit hyperactivity disorder: a randomized clinical trial. Front Psychol. 2024;15:1293244. doi:10.3389/fpsyg.2024.1293244. PMID:38434955; PMCID:PMC10906662.
16. Charach A, Fernandez R. Enhancing ADHD medication adherence: challenges and opportunities. Curr Psychiatry Rep. 2013;15(7):371. doi:10.1007/s11920-013-0371-6. PMID:23712722; PMCID:PMC3718998.
17. Li K. Religion and medicalization: the case of ADHD. J Sci Study Relig. 2013;52(2):309-327. doi:10.1111/jssr.12023.
18. Allen W. A Critical and Exegetical Commentary on the Gospel According to St. Matthew. International Critical Commentary. T&T Clark; 1907. Matthew 9:9-13. https://biblehub.com/commentaries/icc/matthew/9.htm
19. Bruce AB. The Synoptic Gospels: Matthew 9. In: Nicoll WR, ed. The Expositor’s Greek Testament. Hodder and Stoughton; 1897. https://biblehub.com/commentaries/egt/matthew/9.htm
20. American Academy of Pediatrics. Conducting a brief suicide safety assessment. Blueprint for Youth Suicide Prevention. Updated February 22, 2024. Accessed August 27, 2026. https://www.aap.org/en/patient-care/blueprint-for-youth-suicide-prevention/strategies-for-clinical-settings-for-youth-suicide-prevention/conducting-a-brief-suicide-safety-assessment/
21. American Academy of Pediatrics. Brief interventions that can make a difference in suicide prevention. Blueprint for Youth Suicide Prevention. Updated February 22, 2023. Accessed August 27, 2026. https://www.aap.org/en/patient-care/blueprint-for-youth-suicide-prevention/strategies-for-clinical-settings-for-youth-suicide-prevention/brief-interventions-that-can-make-a-difference-in-suicide-prevention/
22. National Institute of Mental Health. Frequently asked questions about suicide. Accessed August 27, 2026. https://www.nimh.nih.gov/health/publications/suicide-faq
23. National Institute of Mental Health. Youth emergency department brief suicide safety assessment guide. ASQ Toolkit. Accessed August 27, 2026. https://www.nimh.nih.gov/research/research-conducted-at-nimh/asq-toolkit-materials/youth-ed/youth-emergency-department-brief-suicide-safety-assessment-guide

---

This article is for education only. It does not diagnose ADHD, recommend starting, stopping, or changing any medication, or replace individualized care. Reading it does not create a clinician-patient relationship.

NP FADY is the editorial and educational presence of Fady Boules, PMHNP-BC. Clinical care is provided through Inland Psychiatric Medical Group (IPMG), a separate entity. Reading this site does not create a clinical relationship.

If you or someone you know is in crisis

• Call 911 or go to your nearest emergency room for any life-threatening emergency.
• 988 Suicide & Crisis Lifeline — call or text 988, available 24/7. En español: marque 988 y oprima 2. Veterans: 988 and press 1, or text 838255.
• Crisis Text Line — text HOME to 741741.
• The Trevor Project (crisis support for LGBTQ+ young people) — call 1-866-488-7386, or text START to 678-678.
• National Sexual Assault Hotline (RAINN) — call 1-800-656-HOPE (4673) or text HOPE to 64673; free, confidential, 24/7. Online chat at RAINN.org/hotline.
• National Domestic Violence Hotline — call 1-800-799-SAFE (7233) or text START to 88788; 24/7, help in 200+ languages. Online chat at TheHotline.org. If your phone or computer may be monitored, calling from a safer device is an option.
• Riverside County — Inland SoCal Crisis Helpline 951-686-HELP (4357), 24/7 (Inland SoCal United Way / 211+, in partnership with RUHS-BH); Community Access, Referral, Evaluation and Support (CARES) Line 800-499-3008, 24/7.
• San Bernardino County — Access Unit (Behavioral Health Helpline) 888-743-1478, 24/7; Mobile Crisis/CCRT 800-398-0018 (24/7, all ages) or text 909-420-0560. Arrowhead Regional Medical Center (ARMC) has a dedicated walk-in adolescent psychiatric ER (ages 13–17).
• Children under 13 — call 911 for immediate danger, contact your county's mobile crisis team (they respond to all ages), or go to the nearest pediatric emergency room.
• California Peer-Run Warm Line (non-crisis — someone to talk to) — call or text 1-855-600-WARM (9276); daytime and evening hours, not a 24/7 line.
• NP Fady (non-emergency) — for routine scheduling or questions, call (909) 707-6261. This line is not monitored for emergencies.